Monoclonal antibodies (mAb) directed against TNF-α (i.e., infliximab, IFX, and adalimumab, ADL) were the first biologics introduced more than a decade ago as therapeutic options for IBD and are still widely used for the treatment of moderate to severe forms of disease [3,4]. Here, TNF is linked to inflammatory bowel disease.